Get the Stockscreener App
5.04
2.33%
-0.12
After Hours:
5.25
0.21
+4.17%
Personalis Inc stock is traded at $5.04, with a volume of 784.49K.
It is down -2.33% in the last 24 hours and up +49.11% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$5.16
Open:
$5.15
24h Volume:
784.49K
Relative Volume:
0.86
Market Cap:
$367.36M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-2.24
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
+21.15%
1M Performance:
+49.11%
6M Performance:
+10.77%
1Y Performance:
+205.45%
1-Day Range:
$4.96
$5.31
1-Week Range:
$3.98
$5.61
52-Week Range:
$1.135
$7.20
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
5.04 | 367.36M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Personalis reiterates 2025 revenue guidance of $80M-$90M with focus on MRD testing growth - MSN
HC Wainwright Raises Personalis (NASDAQ:PSNL) Price Target to $9.00 - Defense World
Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth - Yahoo Finance
Barclays PLC Acquires 43,900 Shares of Personalis, Inc. (NASDAQ:PSNL) - The AM Reporter
JPMorgan Chase & Co. Has $34,000 Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Barclays PLC Increases Stock Holdings in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis stock price target raised to $9 at H.C. Wainwright - Investing.com Australia
Personalis Inc.: Strong Financial Performance and Promising Future Prospects Drive Buy Rating - TipRanks
Will Personalis' Testing Growth And MRD Strategy Pay Off In 2025? - Nasdaq
Analyst Expectations For Personalis's Future - Benzinga
Personalis stock price target raised to $9 at H.C. Wainwright By Investing.com - Investing.com India
Personalis, Inc. (NASDAQ:PSNL) Q1 2025 Earnings Call Transcript - Insider Monkey
Personalis (PSNL) Receives Price Target Boost from Analyst | PSNL Stock News - GuruFocus
H.C. Wainwright Increases Price Target for Personalis (PSNL) to $9 | PSNL Stock News - GuruFocus
Personalis Reports Strong Q1 Growth in Genomics - TipRanks
Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... - Yahoo Finance
Earnings call transcript: Personalis beats Q1 2025 earnings, stock rises By Investing.com - Investing.com South Africa
Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong R - GuruFocus
Personalis Reports First Quarter 2025 Financial Results - BioSpace
Personalis: Q1 Earnings Snapshot - CTPost
Personalis (PSNL) Q1 2025 Earnings Reflects Strong Growth in Molecular Tests - GuruFocus
Personalis (PSNL) Q1 2025 Earnings Reflects Strong Growth in Mol - GuruFocus
Earnings call transcript: Personalis beats Q1 2025 earnings, stock rises - Investing.com
Personalis Inc (PSNL) Q1 2025 Earnings: EPS of -$0.24 Beats Esti - GuruFocus
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Personalis Inc (PSNL) Q1 2025 Earnings: EPS of -$0.24 Beats Estimate, Revenue at $13.6M Misses Estimate - GuruFocus
PSNL Projects Diverse Revenue Streams Across Multiple Segments | PSNL Stock News - GuruFocus
Personalis (PSNL) Reports Strong Q1 Revenue and Testing Growth | PSNL Stock News - GuruFocus
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 37% But Its P/S Still Looks Reasonable - simplywall.st
Invesco Ltd. Invests $82,000 in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis Inc (PSNL) Q1 2025 Earnings Report Preview: What To E - GuruFocus
Personalis Inc (PSNL) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
Personalis Inc (PSNL) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Market Momentum Report: Personalis Inc (PSNL)’s Negative Close at 3.78 - DWinneX
Results from Personalis Inc (PSNL) show potential - uspostnews.com
Examining the Potential Price Growth of Personalis Inc (PSNL) - knoxdaily.com
Personalis (PSNL) Reveals Promising Interim Results in Colorecta - GuruFocus
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study - BioSpace
Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Rel - GuruFocus
Investor’s Delight: Personalis Inc (PSNL) Closes Weak at 4.14, Down -1.90 - DWinneX
Gaining Ground: Personalis Inc (PSNL) Closes Lower at 3.51, Down -3.04 - DWinneX
PSNL Stock Sees Surge of Approximately 12.88% in Last Five Days - knoxdaily.com
Several Personalis Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Personalis and Academic Partners to Present Latest Data on UltraNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
Personalis Inc (PSNL) produces promising results - uspostnews.com
Personalis to Announce First Quarter 2025 Financial Results - BioSpace
Is Personalis, Inc. (PSNL) the Best Multibagger Penny Stock to Buy According to Billionaires? - Insider Monkey
10 Best Multibagger Penny Stocks to Buy According to Billionaires - Insider Monkey
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection | PSNL Stock News - GuruFocus
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection - Business Wire
LPL Financial LLC Sells 6,773 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):